Actively Recruiting
High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With Nintedanib
Led by University of British Columbia · Updated on 2025-01-17
88
Participants Needed
8
Research Sites
574 weeks
Total Duration
On this page
Sponsors
U
University of British Columbia
Lead Sponsor
B
Boehringer Ingelheim
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose is to determine if patients with idiopathic pulmonary fibrosis (IPF) taking nintedanib will have improved exercise endurance, breathlessness and quality of life if breathing 60% oxygen compared to standard of care during an 8 week exercise training program.
CONDITIONS
Official Title
High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With Nintedanib
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 19 years or older
- Diagnosed with idiopathic pulmonary fibrosis (IPF) according to official criteria
- Suitable candidate for pulmonary rehabilitation
- Currently prescribed or taking nintedanib
- Able to walk 50 meters or more in 6 minutes
- Oxygen saturation of 92% or higher at rest while breathing room air
- Clinically stable for at least 6 weeks before the study
You will not qualify if you...
- Contraindication to nintedanib treatment according to Canadian guidelines
- Contraindication to exercise testing, such as serious heart, muscle, or nerve conditions
- Other major non-lung diseases that could limit exercise ability or oxygen use
- Forced vital capacity (FVC) less than 50% or diffusion capacity (DLCO) less than 25%
- Participation in a pulmonary rehabilitation program within the last 6 months
- Use of prednisone over 10 mg/day for more than 2 weeks within 3 months before the study
- Use of pirfenidone within 4 weeks before screening
- Significant emphysema as shown by CT scan or lung function tests
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 8 locations
1
University of Calgary
Calgary, Alberta, Canada, T3M1M4
Completed
2
University of Alberta
Edmonton, Alberta, Canada, T6G 2R3
Actively Recruiting
3
UBC Okanagan
Kelowna, British Columbia, Canada, V1V 1V7
Completed
4
St. Paul's Hospital
Vancouver, British Columbia, Canada, V6Z1Y6
Actively Recruiting
5
McMaster University
Hamilton, Ontario, Canada, L8S 4L8
Actively Recruiting
6
Queens University
Kingston, Ontario, Canada, K7L 3N6
Completed
7
McGill University
Montreal, Quebec, Canada, H3A 0G4
Completed
8
Laval University
Québec, Canada, G1V 0A6
Completed
Research Team
L
Lynda Lazosky
CONTACT
S
Satvir S Dhillon, MSc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here